1. Home
  2. /
  3. Venture Capital
  4. /
  5. Mablink Bioscience announces a...

Venture Capital

Mablink Bioscience announces a €31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners

14 October 2022
Mablink Bioscience, a biotechnology company aiming to transform cancer therapy using next-generation antibody-drug conjugates (ADCs), announced today that it has raised a €31 million Series A funding round to advance its lead candidate to the clinic and to build a pipeline of ADCs using its proprietary platform technology. The round was led by Sofinnova Partners and Mérieux Equity Partners, with participation from existing investors.Mablink Bioscience (“Mablink”), a biotechnology company aiming to transform cancer therapy using next-generation antibody-drug conjugates (ADCs), announced today that it has raised a €31 million Series A funding round to advance its lead candidate to the clinic and to build a pipeline of ADCs using its proprietary platform technology. The round was led by Sofinnova Partners and Mérieux Equity Partners, with participation from existing investors.

Download

Press Release
Download

Related News

arrow-up-right
arrow-up-right
arrow-up-right